Bellevue Group AG reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 37.9% in the 1st quarter, Holdings Channel reports. The firm owned 1,800 shares of the medical research company’s stock after selling 1,100 shares during the quarter. Bellevue Group AG’s holdings in IQVIA were worth $348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. CVA Family Office LLC bought a new position in IQVIA in the first quarter worth $29,000. TRU Independence Asset Management 2 LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Encompass Wealth Advisors LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Alpha Paradigm Partners LLC acquired a new position in IQVIA during the fourth quarter worth $28,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in IQVIA during the first quarter worth $33,000. 87.02% of the stock is owned by hedge funds and other institutional investors.
Shares of IQV opened at $242.80 on Friday. The company has a debt-to-equity ratio of 1.94, a quick ratio of 1.15 and a current ratio of 1.15. IQVIA Holdings Inc. has a 1 year low of $133.18 and a 1 year high of $244.95. The company has a market capitalization of $46.54 billion, a PE ratio of 115.62, a P/E/G ratio of 2.23 and a beta of 1.46. The stock’s 50-day moving average is $227.58.
Several research analysts have issued reports on the company. Truist increased their price objective on IQVIA from $235.00 to $260.00 in a research note on Monday, April 26th. Deutsche Bank Aktiengesellschaft raised their target price on IQVIA from $200.00 to $244.00 and gave the company a “buy” rating in a research note on Friday, April 23rd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on IQVIA from $225.00 to $265.00 in a research note on Friday, April 23rd. Piper Sandler raised their target price on IQVIA from $179.00 to $204.00 and gave the company a “neutral” rating in a research note on Thursday, February 11th. Finally, Jefferies Financial Group raised their target price on IQVIA from $259.00 to $273.00 and gave the company a “buy” rating in a research note on Friday, April 23rd. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. IQVIA currently has a consensus rating of “Buy” and an average price target of $241.79.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: The role of implied volatility with call option volume
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.